Erythropoietin and progression of CKD

Slides:

Advertisements

Similar presentations

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup

Advertisements

Steven Fishbane, Jeffrey S. Berns, M.D. Kidney International

F.H. Bender, J. Bernardini, B. Piraino Kidney International

Erythropoietin should be part of congestive heart failure management

Volume 70, Issue 10, Pages (November 2006)

Renal manifestations in Fabry disease and therapeutic options

Erythropoietin should be part of congestive heart failure management

Impact of new dialysis solutions on peritonitis rates

The case ∣ A young woman with abdominal discomfort and a mass

Prehypertension and chronic kidney disease: the ox or the plow?

Progression of renal failure and hypertensive nephrosclerosis

John P. Middleton, Patrick H. Pun Kidney International

M. Fukagawa, S. Nakanishi, J.J. Kazama Kidney International

Haiyan Wang, Luxia Zhang, Jicheng Lv Kidney International

Volume 71, Issue 8, Pages (April 2007)

Volume 70, Pages S21-S25 (December 2006)

Volume 77, Issue 1, Pages 5-6 (January 2010)

Anemia as a risk factor for chronic kidney disease

F.H. Bender, J. Bernardini, B. Piraino Kidney International

Comorbidity and confounding in end-stage renal disease

D. Batlle, P. Ramadugu, M.J. Soler Kidney International

A new era in phosphate binder therapy: What are the options?

Proinflammatory effects of iron sucrose in chronic kidney disease

Targets to retard the progression of diabetic nephropathy

Volume 70, Issue 11, Pages (December 2006)

Joseph W. Eschbach, John W. Adamson Kidney International

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

The role of protein kinase C activation in diabetic nephropathy

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S. Bianchi, R. Bigazzi, V.M. Campese

Volume 73, Pages S5-S17 (April 2008)

Volume 71, Issue 6, Pages (March 2007)

Volume 70, Issue 12, Pages (December 2006)

Volume 70, Issue 7, Pages (October 2006)

Fructose intake as a risk factor for kidney stone disease

Recent experience with high-dose intravenous iron administration

An unusual cause of acute renal failure

The third World Kidney Day: Looking back and thinking forward

Impact of gender on the renal response to angiotensin II

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 81, Issue 3, Pages (February 2012)

Microbiology and outcomes of peritonitis in North America

Methods for guideline development

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Volume 57, Issue 1, Pages (January 2000)

Volume 71, Issue 4, Pages (February 2007)

Volume 80, Issue 3, Pages (August 2011)

Volume 87, Issue 5, Pages (May 2015)

Volume 69, Issue 5, Pages (March 2006)

Volume 75, Issue 3, Pages (February 2009)

Clinical benefits of slowing the progression of renal failure

Organ transplantation goes to the movies

Volume 70, Pages S84-S90 (November 2006)

Atherosclerotic renal artery stenosis and reconstruction

Volume 80, Issue 10, Pages (November 2011)

Cellular contributions to glomerular size-selectivity

Is it the low-protein diet or simply the salt restriction?

Volume 68, Issue 5, Pages (November 2005)

Is complement a target for therapy in renal disease?

Volume 70, Issue 3, Pages (August 2006)

Volume 70, Issue 6, Pages (September 2006)

Volume 70, Issue 5, Pages (September 2006)

Volume 62, Issue 5, (November 2002)

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Volume 69, Issue 8, Pages (April 2006)

In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression B.O. Eriksen, O.C. Ingebretsen Kidney.

Volume 80, Issue 9, Pages (November 2011)

Volume 61, Issue 4, Pages (April 2002)

Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Danilo Fliser, Jan T. Kielstein, Hermann Haller, Stefanie M. Bode-Böger Kidney.

Presentation transcript:

Erythropoietin and progression of CKD F.H. Bahlmann, J.T. Kielstein, H. Haller, D. Fliser Kidney International Volume 72, Pages S21-S25 (November 2007) DOI: 10.1038/sj.ki.5002484 Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 1 Erythropoietin and nitric oxide bioavailibility. Effects of asymmetric dimethylarginine (ADMA; 3 mg/kg body weight) and rHuEPO (5000 U/kg body weight) alone or in combination (n=15 per group) on (a) glomerular filtration rate and (b) effective renal plasma flow in normotensive C57/Bl6 mice. Data are presented as changes from baseline, that is placebo injection. +P<0.05 vs baseline. #P<0.05 – rHuEPO vs ADMA injection. Kidney International 2007 72, S21-S25DOI: (10.1038/sj.ki.5002484) Copyright © 2007 International Society of Nephrology Terms and Conditions